Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TARIS Biomedical

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Keytruda gains NICE clearance in first line bladder cancer

MSD extends advantage in immunotherapy with Cancer Drugs Fund clearance

- PMLiVE

NICE says OK to Keytruda for bladder cancer via the CDF

Becomes the first immunotherapy recommended for UC after chemotherapy

- PMLiVE

MSD’s Keytruda wins bladder cancer indication in Japan

Becomes first anti-PD1 approved in the country for previously treated UC

J&J launches digital skincare challenge

Seeks start-ups focused on tackling areas such as skin health adherence treatment

- PMLiVE

MSD’s Keytruda wins new bladder cancer indication in Europe

Will treat locally advanced or mUC patients

- PMLiVE

Lilly pitches Cyramza at bladder cancer

Pharma firm is now armed with phase III data from its RANGE study

- PMLiVE

Keytruda is first FDA-approved drug for molecular indication

Indicates a significant development in the shift towards personalised medicine

- PMLiVE

Merck takes on Roche with first-line bladder OK for Keytruda

FDA awards accelerated approval for mUC patients

Roche Basel Switzerland

Tecentriq bladder cancer approval in doubt after trial failure

The PD-L1 inhibitor failed to extend overall survival in a phase III study

AstraZeneca AZ

AZ gets first OK for PD-L1 inhibitor durvalumab

US regulators also approve Roche’s Ventana

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links